1 rich Libsyn https://www.libsyn.com 300 600 Some people with cystic fibrosis have seen life-changing results from Trikafta, but not every patient responds to the treatment. The University of Kansas Health System looks at the research helping the group of CF patients who have been left behind by current therapies. Dr. Steve Stites is joined by cystic fibrosis patient Jason White, pulmonologist and critical care specialist Dr. Joel Mermis, and Dr. Matthias Salathe, Chief Research Officer for the University of Kansas and Chief Science Officer of The University of Kansas Health System. Together, they explain how CFTR mutations, theratyping, swab testing, and gene therapy clinical trials may help identify new treatment options for people living with cystic fibrosis and those with the common F508del mutation. Open Mics With Dr. Stites http://www.kansashealthsystem.com <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/41362650/height/300/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="300" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/item/41362650